Clinical trial
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or…
NCT00005631 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005631 |
|---|---|
| Title | Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma |
| Official title | Cytoreduction and Stem Cell Mobilization With Rituximab and ICE for Patients With Refractory or Relapsed CD20+ B-Cell IGL Eligible for ASCT: The RICE Protocol |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, rituximab, carboplatin, etoposide, ifosfamide |
| Start date | Nov 1, 1999 |
| Primary completion | Nov 1, 2002 |
| Completion | Nov 1, 2002 |
| First posted | Feb 16, 2004 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: